Clinical value of interleukin - 6 as a potential biomarker for bronchogenic carcinoma

Background: Interleukin - 6 is found to be involved in various cancer types but countable studies has investigated its role in cancer lung. Objectives: The purpose of this research was to assess Interleukin-6 levels in bronchoalveolar lavage (BAL) and serum of cases with cancer lung and cases with benign lung conditions, and to determine its diagnostic utility for cancer lung. Subjects and Methods: This prospective interventional analytic study was conducted 40 cases at the Chest Department of Tanta University Hospitals. Cases were divided into two distinct groups: Group 1 comprised twenty individuals with bronchogenic carcinoma, while Group 2 comprised twenty individuals with non-malignant lung illnesses with established causes. All cases received a clinical examination, demographic information, and standard investigations. Using ELISA, the expression of interleukin-6 in BAL and serum was analysed. Results: Interleukin-6 levels were elevated in the BAL and serum of cancer cases versus the control group. Interleukin-6 levels in BAL and serum were positively correlated with advanced clinical stages of cancer lung, as were Interleukin-6 levels in BAL and serum. Conclusions: High BAL Interleukin-6 levels were associated with advanced clinical stage of cancer lung and correlated positively with serum Interleukin-6 levels. BAL Interleukin-6 was determined to be a molecular biomarker for cancer lung diagnosis and prognosis based on its high sensitivity and specificity in detecting lung carcinoma.